Cost-effectiveness and public health impact of recombinant zoster vaccine versus no herpes zoster vaccination in selected populations of immunocompromised adults in Canada
RZV in Canada improves public health outcomes and is likely cost-effective for several IC conditions.
Authors
- Katherine A. Hicks (ORCID: https://orcid.org/0000-0002-1058-3401)
- Justin Carrico (ORCID: https://orcid.org/0000-0002-4659-9309)
- Cheryl Ng (ORCID: https://orcid.org/0000-0002-1707-2305)
- Dessi Loukov (ORCID: https://orcid.org/0000-0002-3413-6884)
- S. George (ORCID: https://orcid.org/0000-0001-6274-9357)
- Desmond Curran (ORCID: https://orcid.org/0000-0002-7423-0111)
Institutions
- GlaxoSmithKline (Belgium) (BE)
- RTI Health Solutions (US)
- GlaxoSmithKline (Canada) (CA)
Publication Details
- Journal
- BMC Health Services Research
- Published
- 2025-04-25
- DOI
- https://doi.org/10.1186/s12913-025-12550-x
- Primary Topic
- Herpesvirus Infections and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00